Pacritinib + Decitabine + Decitabine and Cedazuridine + Azacitidine
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Accelerated Phase Myeloproliferative Neoplasm
Conditions
Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm
Trial Timeline
Mar 2, 2026 → Dec 31, 2028
NCT ID
NCT07148947About Pacritinib + Decitabine + Decitabine and Cedazuridine + Azacitidine
Pacritinib + Decitabine + Decitabine and Cedazuridine + Azacitidine is a phase 2 stage product being developed by Swedish Orphan Biovitrum for Accelerated Phase Myeloproliferative Neoplasm. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07148947. Target conditions include Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm.
What happened to similar drugs?
0 of 1 similar drugs in Accelerated Phase Myeloproliferative Neoplasm were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07148947 | Phase 2 | Recruiting |
Competing Products
4 competing products in Accelerated Phase Myeloproliferative Neoplasm
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Blinatumomab + Cytarabine + Methotrexate + Ponatinib | Amgen | Phase 2 | 42 |
| BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + [14C] BMS-813160 + Placebo + BMS-813160 + BMS-813160 | Bristol Myers Squibb | Phase 1 | 29 |
| dasatinib + dasatinib | Bristol Myers Squibb | Phase 3 | 40 |
| Ruxolitinib + Enasidenib | Incyte | Phase 2 | 32 |